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Hormones can transmit signals through adenosine 3’,5’-monophosphate (cAMP) to precise 
intracellular locations.  The fidelity of these responses relies on the activation of localized 
protein kinase A (PKA) holoenzymes.  Association of PKA regulatory (RII) subunits with 
A-kinase anchoring proteins (AKAPs) confers location, and catalytic (C) subunits 
phosphorylate substrates. Single-particle electron microscopy demonstrated that AKAP79 
constrains RII-C sub-assemblies within 150 to 250Å of its targets.  Native mass 
spectrometry established that these macromolecular assemblies incorporated 
stoichiometric amounts of cAMP.  Chemical-biology and live-cell imaging techniques 
revealed that catalytically active PKA holoenzymes remained intact within the cytoplasm.  
In contrast, little, if any PKA activity was detected in the nucleus.  Hence the parameters of 
anchored PKA holoenzyme action are much more restricted than originally anticipated.  
 
Summary: PKA catalytic subunit does not dissociate from AKAP-anchored PKA holoenzymes 
at physiologically relevant cAMP concentrations. 
 
 
Classical in vitro biochemistry and elegant structural studies have led to a commonly held view 
that active PKA catalytic subunit dissociates from the regulatory subunit dimer in the presence of 
excess cAMP (1-4).  Yet the utility of this rudimentary mechanism inside cells remains unclear 
(5).  Single-particle negative-stain electron microscopy (EM) analysis of AKAP79:PKA 
holoenzyme complexes (AKAP79:2RII:2C) detected a range of conformationally distinct species 
(Fig. 1, A through D and fig. S1). A set of ~14,000 particles was subjected to reference-free 2D 
classification using RELION (6).  Poorly-aligned classes were discarded over multiple iterations 
to reveal an ensemble of three-lobed assemblies in which the peripheral densities are observed at 
different distances from each other.  These range from 150Å in the compact configuration to 
250Å in the extended conformation (Fig. 1E). The tandem peripheral lobes represent the 
catalytic subunit in complex with the cAMP binding domains of RII (7), whereas the central 
density represents the A-kinase anchoring protein-RII dimer interface (Fig. 1E).  Thus AKAP79 
constrains each sub-assembly of regulatory and catalytic subunits to within 250Å of substrates. 
We surmise that the restricted movement of the anchored C subunit in this configuration 
augments phosphorylation of local substrates that are either interacting with the AKAP (Fig. 1F) 
or in proximity to the peripheral lobes of the extended PKA holoenzyme (Fig. 1G). 
 
An implication of our structural model is that although local cAMP production stimulates kinase 
activity, AKAP79:2RII:2C assemblies can remain intact.  Native mass spectrometry (MS) allows 
the measurement of molecular mass and is used to determine the stoichiometry of intact protein 
complexes in the gas phase (8-10).  In the presence of cAMP, which co-purifies with RII, we 
observed higher order complexes, including the intact 2RII:2C PKA holoenzyme and the 
pentameric AKAP79:2RII:2C assembly (Fig. 1H, fig. S1 and tables S1-2).  These experiments 
infer a minimal disruption of the AKAP-PKA architecture even in the presence of cAMP. 
 
To address the relative stability of the pentameric AKAP79:2RII:2C assembly in the presence of 
elevated cAMP we performed pulldown experiments with a fragment of the anchoring protein 
AKAP79297-427.  Retention of anchored C subunits in the presence of increasing concentrations of 
cAMP was assessed by quantification of Coomassie blue stained protein (Fig.1I and inset).  At 
physiological concentrations of cAMP (1 to 2 µM) most of the C subunit (~70 to 80%) remained 
associated with the AKAP79297-427-RII complex (Fig.1I and inset).  Substantial release of the C 
subunit was only evident at supraphysiological levels of cAMP (Fig. 1I; 10 to 90 µM) and no 
change in binding of RII to AKAP79297-427 was observed.  In control experiments, 5’-AMP 
(100µM), a degradation product of cAMP, did not alter anchored holoenzyme composition (Fig. 
1I).  Thus physiological amounts of cAMP promote minimal release of the C subunit from the 
anchored holoenzyme in vitro.   
 
Additional studies used high resolution native MS to evaluate cAMP occupancy in PKA 
holoenzyme complexes.  At basal cAMP concentrations, multiple charge states of 2RII:C sub-
complexes were observed between m/z 5700 to 6300.  These species preferentially contained 2, 
but up to 4, molecules of cAMP (fig. S1). When analysis was done at higher concentrations of 
cAMP (5 µM), the predominant species exhibited cyclic nucleotide occupancy of 4 moles per 
RII dimer (fig. S1 and table S3).  Of note, the C subunit remained attached under these 
conditions (fig. S1).  Thus, we can conclude that a substantial proportion of the PKA catalytic 
subunit remained associated with the AKAP79297-427-RII dimer when cAMP-binding sites were 
occupied.  
 
For a more stringent in situ test, we monitored the integrity of cellular AKAP-PKA complexes in 
response to ligand activation.  AKAP79 or AKAP18g complexes were immunoprecipitated from 
cell lysates prepared after stimulation of cells with the b-adrenergic agonist isoproterenol (Iso; 
1µM).  Immunoblot analysis detected equivalent amounts of C subunit in samples from cells 
stimulated with isoproterenol or vehicle control (Fig. 2, A and B; top panels, lane 2).  Local 
cAMP flux is controlled through a balance of second messenger production by adenylyl cyclases 
and degradation by phosphodiesterases (PDEs) (11, 12).  Cells were stimulated with 
isoproterenol in the presence of the general PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX), 
the selective PDE3 inhibitor milrinone, or the PDE4-specific inhibitor rolipram (13, 14).  The 
composition of AKAP79-PKA complexes was assessed by immunoblot.  Intact complexes were 
detected in control and Iso treated samples (Fig. 2C, lanes 1 and 2).  Inclusion of rolipram 
promoted full dissociation of the C subunit (Fig. 2C, lane 3).  Likewise, application of IBMX 
induced release of the C subunit from AKAP complexes (Fig. 2C, lane 5). In contrast, inclusion 
of milrinone had little effect, indicating that PDE3 is non-functional in these AKAP79-PKA 
microdomains (Fig. 2C, lane 4).  Kinase activation was monitored by immunoblot detection of 
phospho-PKA substrates (Fig. 2C, bottom panel).  Similar findings were obtained upon analysis 
of AKAP18g complexes, and when prostaglandin E1 (PGE1) or epinephrine were used as 
agonists (fig. S2).  Treatment with rolipram alone did not activate PKA or release C subunits 
(Fig. 2C, lane 6).  Thus, native production of cAMP in response to physiological effectors of 
GPCR signaling appears not to promote C subunit release from anchored PKA holoenzymes.   
 
Förster Resonance Energy Transfer (FRET) was used to investigate PKA holoenzyme 
composition in real time (15, 16).  Initially, we used RII conjugated to cyan fluorescent protein 
(RII-CFP) and C-subunit conjugated to yellow fluorescent protein (C-YFP) as intermolecular 
FRET probes to monitor the integrity of the PKA holoenzyme after agonist stimulation of cells 
(Fig. 2D).  Isoproterenol promoted minimal change in the CFP/YFP FRET ratio over time 
courses of 400 sec (Fig. 2, E and H, black), consistent with negligible dissociation of the PKA 
holoenzyme.  In contrast, pre-incubation of cells with rolipram before stimulation with β-
adrenergic agonist triggered a pronounced and time-dependent reduction in the FRET ratio (Fig. 
2, F and H; red). Thus, dissociation of the PKA holoenzyme only occurred if cAMP accumulated 
to supraphysiological concentrations.  Pretreatment of cells with the PDE3 inhibitor milrinone 
had little effect on the FRET response (Fig. 2, G and H, grey).  Comparable FRET recordings 
were obtained when PGE1 was used as the agonist (fig. S2).   
 
The ICUE3 FRET biosensor detects agonist-responsive accumulation of cAMP (Fig. 2I) (17).  
Stimulation of cells with isoproterenol or PGE1 promoted transient increases in the FRET signal 
(Fig. 2J, black and fig. S2). This response was enhanced by addition of rolipram (Fig. 2J, red and 
fig. S2).  However, the highest amounts of cAMP production (15 fold above physiological 
levels) were recorded upon application of forskolin, a direct activator of adenylyl cyclases and 
common tool in cAMP research (Fig. 2J, blue).  Thus, forskolin sustains supraphysiological 
accumulation of cAMP to concentrations far above those induced by b-agonists.    
 
We investigated the effect of recurrent stimulation of cAMP synthesis on PKA holoenzyme 
integrity with the same biosensors.  After an initial pulse of isoproterenol, the drug was washed 
out for 500 seconds before application of a second stimulus (Fig. 2, K and L).  Intermolecular 
FRET revealed that RII-CFP and C-YFP remained in proximity over the duration of these 
experiments (Fig. 2K, black).  As expected, co-stimulation of cells with isoproterenol and 
rolipram initiated cycles of holoenzyme dissociation and reformation (Fig. 2K, red).  
Complementary biochemical experiments revealed that washout of rolipram and isoproterenol 
promoted reformation of AKAP79-PKA holoenzyme over a similar time course (fig. S2).  Using 
the ICUE3 biosensor, we demonstrated that isoproterenol induces a transient rise in the cellular 
concentration of cAMP that approaches baseline during washout (Fig. 2L, black).  A second 
application of agonist then initiates another round of cAMP production.  In contrast, co-
stimulation with rolipram produces two additive phases of intracellular cAMP accumulation 
(Fig. 2L, red).  Collectively these experiments demonstrate that PDE4 modulates cAMP 
microdomains surrounding anchored and intact PKA holoenzymes   
 
Proximity ligation assays (PLA) detect endogenous protein-protein interactions that occur within 
40 to 60 nm (18).  Unstimulated and agonist-treated HEK293 cells were fixed, stained with 
antibodies to RII and C subunits and subjected to the PLA amplification protocol prior to 
imaging of PLA puncta (fig. S2).  Image intensity profiling of PLA puncta showed the 
distribution of intact PKA holoenzymes (Fig. 2, M through O).  The number of the puncta per 
cell indicated the extent of RII-C interactions under each experimental condition (Fig. 2P). 
Treatment with isoproterenol did not appreciably change the PLA signal as compared to 
unstimulated control cells (Fig. 2, M, N and P).  In contrast, treatment of cells with isoproterenol 
and rolipram reduced the number and intensity of PLA puncta (Fig. 2, O and P).  Immunoblot 
detection of endogenous RII and C in HEK293 cell lysates confirmed the same trend (fig. S2). 
Thus physiological agonists that mobilize cAMP signaling promote very little dissociation of 
native PKA holoenzymes inside cells.  
 
To test whether covalent coupling of RII to the C subunit would alter PKA action inside cells, we 
generated a construct that encodes RIIa and Ca in one polypeptide, creating a non-dissociable 
PKA fusion enzyme designated “R2C2” (Fig. 3A). To exploit this tool in a simplified genetic 
background, we used CRISPR-Cas9 editing to disrupt the PRKAR2A, PRKAR2B and PRKACA 
genes in U2OS human osteosarcoma cells (triple KO U2OSR2A/R2B/CA).  Loss of protein 
expression due to gene-editing was confirmed by immunoblot (Fig. 3B, lane 2, upper three 
panels). Rescue upon expression of R2C2 was confirmed by immunoblot (Fig. 3C, lane 3; top 
panel).  Activity profiling using the phospho-PKA substrates antibody confirmed that 
isoproterenol responsive PKA activation was reduced to baseline levels in triple KO 
U2OSR2A/R2B/CA cells (fig. S3). Further removal of the PRKACB gene was unsuccessful, 
suggesting that ablation of both PRKAC genes could be a lethal event.  Yet, quadruple KO 
U2OSR2A/R2B/CA/CB cells survived if gene editing was performed in cells stably expressing murine 
R2C2 (fig. S3).  
 
We next used AKAR4 biosensors that measure PKA activity via changes in FRET to assess how 
compartmentalization affects free and fused PKA activity (Fig. 3D) (19).  Rapid increases in 
cytoplasmic FRET responses were recorded in U2OSR2A/R2B/CA cells rescued with murine RIIa 
and Ca (Fig. 3, E and F, orange).  Importantly, cells expressing the R2C2 fusion protein 
generated isoproterenol responses of similar magnitude and duration (Fig. 3, E and F, green).  
There was no detectable FRET response to agonist stimulation in the U2OSR2A/R2B/CA deletion 
background or in cells expressing a catalytically inactive mutant of the RII-C fusion (R2C2K72A; 
Fig. 3, E and F, grey and fig. S3).  Thus, covalent coupling of the PKA subunits does not impair 
cAMP signaling in the cytoplasm and can reconstitute endogenous kinase activity.  
 
To further underscore this latter point, we used rapamycin-regulated heterodimerization to 
“pharmacologically lock” FRB-domain tagged C-subunits (FRB-C) to FK506-binding protein 
domain tagged RII dimers (FKBP-RII) in the context of the AKAP18 complex.  In this system, 
the small molecule rapamycin bridges the tagged proteins to maintain a stable complex (Fig. 
3G). Immunoblot analyses of AKAP18 immune complexes from cells expressing FKBP-RII and 
FRB-C revealed that both proteins were associated after stimulation of cells with isoproterenol in 
the absence of rapamycin (Fig. 3H, top panel, lane 2).  As before, administration of isoproterenol 
and rolipram together caused supraphysiological accumulation of cAMP and abolished this 
interaction (Fig. 3H, top panel, lane 3).  Conversely, application of rapamycin locks the FRB-
C/FKBP-RII sub-complex together, even when cells are treated with isoproterenol plus rolipram 
(Fig. 3H, top panel, lane 6).  
 
Cell-based studies in triple knockout U2OS cells confirmed that cytoplasmic FRET responses to 
isoproterenol were robust (Fig. 3I, orange), even after pharmacological locking of this modified 
PKA holoenzyme with rapamycin (Fig. 3I, blue).  Isoproterenol treatment of cells in the presence 
of rolipram has no additional effect (fig. S3).  Thus cytoplasmic PKA signaling is sustained 
when the C subunit and the RII dimer are chemically constrained. 
 
We monitored nuclear PKA activity with an AKAR biosensor targeted to the nucleus via a 
nuclear localization signal (AKAR4NLS) (19).  FRET signals were negligible in both wildtype 
and U2OSR2A/R2B/CA cells stimulated with isoproterenol (fig. S3, Fig. 3J and 3K, grey).  In fact, 
detection of any nuclear FRET required supraphysiological accumulation of cAMP upon 
stimulation of adenylyl cyclases with 20µM forskolin in the presence of IBMX for 30 minutes.  
Under these extreme conditions, rescue with murine RIIa and Ca resulted in a gradual increase 
in FRET over 15 minutes (Fig. 3, J and K, orange).  In contrast, cells expressing R2C2 showed 
greatly diminished nuclear FRET responses (Fig. 3, J and K, green).  Chemically locking FRB-C 
subunits to FKBP-RII dimers with rapamycin also impairs the nuclear AKAR4 FRET responses 
in cells treated with isoproterenol and rolipram (fig. S3). Together, these results demonstrate that 
cytoplasmic activation of PKA is a rapid event, whereas nuclear signaling requires persistent and 
supraphysiological accumulation of cAMP. 
 
This latter finding has ramifications for nuclear cAMP-responsive events.  The cAMP response 
element binding protein CREB is a transcription factor that is a substrate for several kinases 
including Akt, MSK1/2 and PKA (20-22).  We used immunofluorescence detection of nuclear 
pSer133 to monitor CREB phosphorylation in situ (23).  Little, if any phosphorylation of CREB 
was evident after stimulation of U2OSR2A/R2B/CA cells with isoproterenol for 30 minutes (Fig. 3, L 
through O).  Expression of R2C2 led to a small increase in the Iso-stimulated nuclear pSer133 
signal (Fig. 3, P through S), whereas overexpression of murine RIIa and Ca strongly augmented 
this response (Fig. 3, T through W).  Amalgamated fluorescence intensities of the pSer133 signal 
(35-55 cells, each condition) are presented in Fig. 3X.  These findings tally with the FRET data 
(Fig. 3K and S3) showing that the R2C2 fusion has limited access to the nucleus.  Hence, PKA 
phosphorylation of CREB and subsequent nuclear transcriptional events may be limited to 
instances of long-term or supraphysiological accumulation of cAMP.  This is in stark contrast to 
hormonal responses that evoke rapid physiological pulses of cAMP to drive anchored PKA 
activation.   
 
We generated an analog-sensitive form of R2C2 that is exclusively modulated by the cell-
permeable kinase inhibitor 1-napthylmethyl-PP1 (1-NM-PP1; Fig. 4A) (24, 25).  Engineering 
this pharmacologically tractable and fused form of PKA was achieved by substituting the 
gatekeeper methionine in the catalytic moiety of R2C2 with alanine (M120A).  In situ 
characterization of this synthetic analog-sensitive kinase in U2OSR2A/R2B/CA cells was achieved 
using an AKAP-derived PKA activity reporter (AKAP18RBS-AKAR4; Fig. 4B).  In cells 
expressing wildtype R2C2, isoproterenol (1µM) stimulation induced a FRET response within 10 
sec that was refractory to 1-NM-PP1 (Fig. 4C, green).  The rate and magnitude of the FRET 
response was attenuated in cells expressing R2C2 M120A, a common property of analog-
sensitive kinases (25).  However, application of 1-NM-PP1 (2µM) to these cells reduced the 
FRET signal to baseline, indicating strong inhibition of the analog-sensitive kinase (Fig. 4C, 
blue).  Thus 1-NM-PP1 is an efficient inhibitor of R2C2 M120A in situ.   
 
We used this chemically controllable form of fused PKA to examine phosphorylation of local 
extra-nuclear substrates.  The mitochondrial anchoring protein D-AKAP-1 sequesters PKA at 
mitochondria to regulate phosphorylation of the pro-apoptotic protein BAD (Fig. 4D) (26).  PKA 
phosphorylation of BAD Ser155 blocks apoptosis through a mechanism involving recruitment of 
14-3-3 proteins to suppress programmed cell death (Fig. 4D) (27-29). BAD phosphorylation on 
serine 155 was robustly stimulated by isoproterenol in WT U2OS cells and this effect was 
blunted in triple knockout cells (fig. S4).  Confocal imaging confirmed that D-AKAP-1 and BAD 
are detected at mitochondria (fig. S4), whereas proximity ligation assays detected puncta that are 
indicative of an interaction between these two proteins (fig. S4).  In triple knockout cells 
expressing the R2C2 WT and R2C2 M120A mutants, immunoblot analysis confirmed that these 
modified kinases effectively phosphorylated BAD Ser155 after treatment of cells with 
isoproterenol (Fig. 4E; top panel, lanes 1-4).  Control immunoblots monitored the expression of 
the PKA fusion enzymes and GAPDH served as loading controls (Fig. 4E; mid and bottom 
panels).  Application of 1-NM-PP1 (2µM) inhibited the activity of R2C2 M120A and blocked 
phosphorylation of BAD Ser155 (Fig. 4E; top panel; lane 6).  Normalized BAD pSer155 data 
from three independent experiments is presented in Fig. 4F.  With this tool, we could test 
whether local activation of PKA is inhibitory toward apoptosis.   
 
We induced apoptosis in triple knockout cells expressing R2C2 M120A by treatment with the 
chemotoxic agent etoposide (Fig. 4, G and H) (30).  Cell death was assessed as accumulation of a 
fluorescent product of caspase 3 or 7-mediated proteolysis (green, Fig. 4G) and nuclear 
condensation observed upon staining DNA with 4',6-diamidino-2-phenylindole (DAPI, magenta, 
Fig. 4G).  Unstimulated cells exhibit low levels of apoptosis (Fig. 4G, left panel and Fig. 4H). 
Etoposide treatment promotes cell death (Fig. 4G, left-mid panel and Fig. 4H).  Stimulation of 
R2C2 activity with b-AR agonists (Iso and formoterol) was protective as it substantially reduced 
the apoptotic index (Fig. 4G, mid-right panel and Fig. 4H).  Application of 1-NM-PP1 blocked 
this protective effect (Fig. 4G, right panel and Fig. 4H, blue).  Thus, fused RII and C subunits 
can substitute for endogenous PKA in the modulation of local cellular events.  
 
Contrary to current dogma, our results show that anchored PKA holoenzymes remain intact or in 
immediate proximity to anchoring sites and substrates in the presence of cAMP, and that fusion 
of the kinase moiety to RII supports cAMP signaling in diverse cellular contexts.  One exception 
seems to be PKA action in the nucleus.  Within this subcellular compartment we detected 
minimal PKA activation, even after sustained accumulation of cAMP to supraphysiological 
levels.  Thus phosphorylation of the transcription factor CREB on serine 133 may not proceed 
directly through PKA.  Three factors can account for this view: 1) the well-documented nuclear 
exclusion of all R subunit isoforms guarantees formation of the PKA holoenzyme solely in the 
cytoplasm (31-35); 2) cytoplasmic retention of intact but active PKA holoenzymes reduces the 
availability of free C subunit to enter the nucleus and 3) the heat-stable inhibitor (PKI) affords a 
failsafe mechanism to rapidly inhibit and export any free C subunit that strays into the nucleus 
(36-38).  Consequently, crosstalk with CREB kinases such as calcium-calmodulin dependent 
protein kinase II (CaMKII), mitogen- and stress-activated protein kinase-1 (MSK1), Akt or 
ribosomal S6 kinase (RSK) isoforms is more likely to manage cAMP responsive transcription 
(22, 39, 40).  
 
Finally, because AKAP79 constrains intact and catalytically active PKA within 150 to 250Å, we 
propose that the range of anchored PKA action is much more restricted than originally 
anticipated (Fig. 1, F and G) (41).  Another prerequisite for this new model is that the location of 
these active zones must coincide with microdomains where cAMP concentrations increase and 
when substrates are available (11, 42). This intricate molecular architecture helps explain how 
common signaling components are assembled to elicit distinct, rapid and transient endocrine 
responses.   
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Fig.1. AKAP-PKA holoenzyme assemblies remain intact upon cAMP stimulation.  (A) SDS-
PAGE and stain-free visualization of a purified complex of AKAP79, RII and C subunits of 
PKA. (B) Stain-free visualization on native gels of intact AKAP79-PKA holoenzyme complex. 
(C-E) Representative negative-stain EM micrographs of AKAP79:2RII:2C single particles. (D) 
Traces outlining the selected particles in (C). (E) Reference-free class averages from RELION 
2D alignment and classification showing range of particle lengths. (F-G) Schematics illustrating 
the flexibility and range of motion in AKAP79-anchored PKA holoenzymes. A compact state 
may favor the phosphorylation of associated substrates (F), while an extended conformation may 
allow PKA to act on multiple distinct local substrates (G).  (H) Zero charge state native nESI 
mass spectrum of RII+C+AKAP297-427 complexes. The stoichiometry of AKAP79297-427 (grey), 
RII (green), C subunit (orange), and cAMP (yellow) is indicated. (I) Percentage of C subunit 
bound to AKAP79297-427–PKA complexes after incubation with increasing cAMP concentrations. 
Data are presented as means ± SEM. Inset shows Coomassie blue staining of proteins in pull-
down experiments. 
  
 
Fig. 2.  Anchored PKA holoenzyme dynamics upon ligand stimulation. Western blot analysis of 
PKA C and RII subunits in (A) AKAP79 or (B) AKAP18g immunoprecipitates (IP) after 
isoproterenol stimulation (Iso).  (C) IP and Western blot analysis of AKAP79 complexes isolated 
in the presence of phosphodiesterase inhibitors.  (D) Schematic depicting RII-CFP and C-YFP 
intermolecular FRET.  (E-H) FRET analysis of holoenzyme dissociation in HEK293 cells.  (E) 
Time course of representative cells (0-400sec) stimulated with isoproterenol. (F) Iso + PDE4 
inhibitor rolipram. (G) Iso + PDE3 inhibitor milrinone. (H) Amalgamated data from 25 
recordings under each experimental condition. (I) Schematic depicting ICUE3 cAMP FRET 
sensor.  (J) ICUE3 FRET recordings show cAMP production in response to Iso (black), Iso + 
rolipram (red), and forskolin (blue).  The number of experiments is indicated.  (K-L) FRET 
analysis upon two trains of hormonal stimulation.  (K) Intermolecular FRET analysis of 
holoenzyme dissociation in HEK293 cells upon two trains of stimulation with isoproterenol 
(black) and Iso + PDE4 inhibitor rolipram (red).  (L) Monitoring cAMP accumulation with 
ICUE3 FRET sensor in response to isoproterenol (black) and Iso + PDE4 inhibitor rolipram 
(red).  Amalgamated data from 25 recordings under each experimental condition. (M-O) 
Proximity ligation (PLA) signal intensity projections show RII-C interactions in (M) 
Unstimulated, (N) Iso-stimulated, and (O) Iso + rolipram treated HEK293 cells. (P) 
Quantification of PLA puncta/cell using Fiji/ImageJ. All data are presented as means ± SEM.  
 
Fig. 3. CRISPR-Cas9 PKA triple knockout and rescue with an RII-C fusion.  (A) Schematic 
depicting the R2C2 PKA fusion enzyme.  (B) Immunoblots confirming knockout of PKA subunit 
proteins: (top) RIIa, (upper-mid) RIIb, (lower-mid) C-subunit. Ponceau (bottom) staining shows 
equal loading in U2OSR2A/R2B/CA cells. (C) Western blotting for PKA C subunit to confirm 
expression of R2C2 fusion. (D) Schematic of AKAR4 PKA activity biosensor.  (E) 
Representative cells showing cytoplasmic AKAR4 FRET response upon rescue with (left) RIIa 
and Ca and (right) R2C2 fusion. (F) Cytoplasmic FRET recordings in triple knockout 
U2OSR2A/R2B/CA cells (grey) and cells rescued with R2C2 fusion (green) or WT RIIa and Ca 
(orange).  (G) Schematic of rapamycin induced heterodimerization of PKA subunits. (H) 
Immunoblots showing that rapamycin chemically locks the PKA holoenzyme at 
supraphysiological concentrations of cAMP. (I) Cytoplasmic FRET recordings in response to Iso 
(1 µM) stimulation in U2OSR2A/R2B/CA cells expressing FKBP-RII and FRB-C in the presence 
(blue) or absence (orange) of rapamycin (100 nM).  (J) Montage of cells showing nuclear 
AKAR4 FRET signals upon rescue with (left) RIIa and Ca, or (right) R2C2 fusion. (K) Nuclear 
FRET recordings in U2OSR2A/R2B/CA cells (grey) and cells rescued with R2C2 fusion (green) or 
wild-type RIIa and Ca (orange).  (L-W) immunofluorescence detection of phospho-CREB 
Ser133 (yellow; panels L, N, P, R, T and V) in U2OSR2A/R2B/CA cells rescued with R2C2 (P, Q, R 
and S) or expression of murine PKA subunits (T & U and V & W).  Composite images (panels 
M, O, Q, S, U and W) reveal staining for RIIa (blue) and actin (grey).  (X) Quantification of 
CREB pSer133 immunofluorescence. All data are presented as means ± SEM. 
 
  
 
Fig. 4. Chemical-genetic and pharmacological control of mitochondrial PKA action.  (A) 
Schematic depicting the introduction of an analog-sensitive kinase mutation into the R2C2 PKA 
fusion enzyme.  The activity of this pharmacologically-controlled fusion kinase was monitored 
in U2OSR2A/R2B/CA cells.  (B) Representative cells showing cytoplasmic AKAR FRET signals at 
selected time points from cells expressing (top) R2C2 and (bottom) the 1-NM-PP1 sensitive 
R2C2 M120A mutant.  The left image in both panels shows expression of the FRET reporter.  
The other panels show pseudo-color images of the FRET intensity at one time point prior to 
stimulation (-45 sec), one time point after stimulation with isoproterenol (105 sec) and a third 
time point after addition of 1-NM-PP1 (415 sec).  (C) Time courses of cytoplasmic AKAR4 
FRET responses to Iso (1 µM, time zero) and 1-NM-PP1 (2 µM, 300 sec) in PKA triple 
knockout cells expressing the (green) R2C2 fusion or (blue) the R2C2 M120A mutant. (D) 
Schematic depicting protective effects of anchored PKA due to phosphorylation of BAD, and 
resultant release of the pro-survival BCL-2 protein.  (E) Inhibition of PKA directed BAD 
pSer155 phosphorylation by 1-NM-PP1 in cells expressing R2C2 M120A. Immunoblot detecting 
(top) BAD pSer155, (mid) R2C2 and (bottom) GAPDH loading controls.  (F) Quantification of 
BAD pSer155 signal from immunoblots from three independent experiments. Data are presented 
as means ± SEM. (G) Fluorescent detection of apoptotic events upon treatment of cells with the 
apoptotic agent etoposide, plus and minus b-agonists and 1-NM-PP1.  Apoptotic cells were 
detected by (green) activation of caspase and (magenta) condensation of DNA. (H) 
Quantification of percent apoptotic cells from (G). The numbers of cells monitored are indicated 
above each column. Data are presented as means ± SEM. 
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Materials and Methods 
cDNAs, Cloning and Mutagenesis 
 
The FRET biosensor constructs for AKAR4NES, AKAR4NLS and ICUE3 were kindly provided by 
Dr. Jin Zhang (UC San Diego). The R2C2 PKA fusion construct was cloned using Gibson 
Assembly of PCR products into pcDNA3.  The construct consists of full length mouse RIIa 
cDNA, a segment encoding a linker peptide 
(WDPGSGSLEAGCKNFFPRSFTSCGSLEGGSAAA), the full-length mouse PKA-Ca cDNA and 
an epitope tag (AAALEHHHHHH*).  Mutagenesis to introduce the “kinase-dead” or analog-
sensitive mutations (Lys507Ala or Met555Ala in the full-length R2C2 polypeptide) was 
performed using inverse PCR with Phusion polymerase (NEB), followed by phosphorylation and 
ligation of free ends.  All oligonucleotides and geneBlock fragments were purchased from 
Integrated DNA Technologies.  All other molecular biology procedures followed standard 
protocols. 
 
Cell Culture 
 
U2OS cells were a gift from Dr. Heidi Hehnly (SUNY Upstate) and were tested by DDC Medical 
with results verified by ATCC STR profiling. HEK293A (ThermoFisher) cells were cultured in 
DMEM-H plus 10% FBS and penicillin/streptomycin (ThermoFisher).  U2OS cells were cultured 
in DMEM-H containing 20 mM HEPES pH 7.4, 10% FBS and pen/strep.  Cells were passaged 
2-3 times per week using TrypLE reagent (ThermoFisher).  U2OSR2A/R2B/CA stably expressing 
R2C2 were created by transfection with the appropriate vectors, selection with G418 (400 
µg/ml) for 2-3 weeks, expansion and screening for expression by immunoblot. 
 
CRISPR-Cas9 Editing of PKA Subunit Genes 
 
Vectors encoding sgRNAs and SpCas9-2A-GFP were provided by Horizon Discovery 
(Cambridge, UK).  Multiple sgRNA sequences were tested for each gene targeted.  A 
combination of three individual vectors that worked in initial experiments were co-transfected 
into U2OS cells using TransIt-LT1 (Mirus).  The guide sequences used are as follows:  
PRKAR2A guide 5: GTACTTCACCCGCCTGCGCG 
PRKAR2B guide 4: ACTCCAGCAGGTCCGCGGGC 
PRKACA guide 3: TTTCACTGAAAGGGAGAGAG 
Single cells were sorted into 96-well plates by FACS according to GFP fluorescence and 
individual clones were expanded for testing.  Clones were first assayed for loss of protein 
expression of RIIa, RIIb and Ca by Western blotting.  Clones that had low or undetectable 
levels of these proteins were further checked for mutations by purification of genomic DNA and 
PCR of the appropriate region.  PCR products were cloned into pCRBluntII (ThermoFisher) and 
8-12 individual colonies were chosen for plasmid DNA mini-prep and sequencing. 
 
Negative Stain Electron Microscopy 
 
MBP-AKAP79-6xHis, 6xHis-PKA catalytic (C) subunit, and RIIa-6xHis regulatory subunit were 
produced in BL21(DE3) pLysS E. coli cells (ThermoFisher). Expression was induced with 0.5 
mM IPTG for 4 h at 37 ˚C. Proteins were purified using immobilized metal affinity 
chromatography (IMAC), followed by size-exclusion chromatography (SEC) using a Superdex 
200 10/300 GL column (GE Healthcare) with SEC buffer (20 mM HEPES, pH 7.5, 200 mM 
NaCl). Individual subunits were incubated at 4˚ C overnight with a molar ratio of 1:2.5:3 
AKAP79:RII:C in order to promote formation of a complete complex. These assemblies were 
subjected to SEC again to isolate fully-formed AKAP79:2RII:2C complexes, which were then 
prepared for EM using the GraFix method (43). Dilute samples were applied to carbon coated 
grids and negative-stained with uranyl formate.  Grids were imaged on a Tecnai T12 TEM at 
0.7-1.5 micron defocus ranges using the Leginon package (44). The initial set of ~14,000 
particles were autopicked using DoGPicker (45).  Particles were refined through multiple rounds 
to a set of 3513 particles and iteratively sorted by reference-free 2D classification using RELION 
(6) until high-quality class averages were obtained. 
 
In vitro Pull-down Assays for AKAP79-PKA Complexes 
 
6xHis-PKA catalytic (C) subunit, RIIa-6xHis regulatory subunit and GST-AKAP79 (amino acids 
297-427) were produced in BL21(DE3)pLysS E. coli cells (Novagen). Expression was induced 
with 0.5 mM IPTG for 18 h at 18°C. Proteins were purified using either immobilized metal affinity 
chromatography (IMAC) or glutathione sepharose, followed by size exclusion chromatography 
using a HiLoad 16/600 Superdex 200 column (GE Healthcare) equilibrated in 50 mM Tris/HCl, 
pH 7.4, 100 mM NaCl, 10 % (v/v) glycerol and 1 mM DTT. Purified GST-AKAP79297-417 
containing a 3C protease cleavage site was incubated on ice for 3 hours with glutathione 
Sepharose beads, washed five times in binding buffer (50 mM Tris pH 7.4, 0.1M NaCl) and 
resuspended at a final concentration of ~2µM AKAP79297-417. C-subunit (~16 µM final 
concentration) and RIIa-subunits (~4 µM final concentration) were incubated with beads in the 
presence or absence of the indicated concentration of cAMP for 20 mins at 30°C with constant 
agitation. The supernatant was then removed, and after three washes in binding buffer, 
complexes were eluted from the beads by incubation with 250 ng of 3C protease for 30 minutes 
at 30°C. Proteins were analysed by SDS-PAGE on a 12% gel. The percentage of C-subunit 
bound to the AKAP:RIIa complexes was calculated by densitometry using Image J software, 
and plotted as a function of cAMP concentration. 
 
Pentamer Formation and Analysis by Ion Mobilization Native Mass Spectrometry 
 
Formation of the pentamer (and associated sub-complexes) was achieved by incubating 
AKAP79297-427 (0.75 µM), RIIa (1.88 µM) and C-subunit (2.25 µM) (molar ratio 1:2.5:3 with a final 
volume of 100 µl) in 20 mM HEPES, 100 mM NaCl overnight at 4 °C. No additional cAMP was 
included. The sample was buffer exchanged into 100 mM NH4OAc, 1 mM Tris (pH 7.5) prior to 
native nESI-MS using a Synapt G2-Si instrument (Waters). The sprayer voltage was ~1.5 kV, 
sampling cone was kept at 150 V, source temperature was 80°C, with the instrument operating 
in mobility mode. Argon pressure in the ion trap and transfer tube was set to 3*10-2 mbar. The 
He cell was 4.5 mbar. Pressure in the ion mobility tube, filled with nitrogen, was 2.8 mbar. Bias 
voltage for transfer from the ion trap to ion mobility cell was adjusted to 50 V.    
 
Ion Mobilization Native Mass Spectrometry 
 
AKAP binding studies were conducted using a Waters Synapt G2-Si instrument. PKA C-subunit 
(1.5 µM), RIIa (1.5 µM) and AKAP79297-417 (3 µM) were incubated for 20 min at 37°C in 100 mM 
NH4OAc and analyzed using borosilicate emitters (Thermo Scientific ES 387). cAMP-dependent 
experiments were performed on a Thermo Exactive Plus EMR instrument. PKA C-subunit (2.5 
µM) and RIIa (2.5 µM) were incubated at room temperature for 10 min in 200 mM NH4OAc, with 
cAMP being added to the final stated concentration and incubated again for 10 min prior to 
nano-Electrospray analysis using borosilicate emitters. 
 
High Resolution Analysis with the Exactive EMR Orbitrap 
 
To determine the stoichiometry of cAMP binding to RII:C complexes, the Exactive EMR Orbitrap 
(ThermoScientific) was operated at a resolution of 17500 (FWHM at m/z 200). The sprayer 
voltage was ~1.5 kV. Source ionization was maintained at 200 V. 
 
Data Deconvolution 
To assist in MS data interpretation, the native mass spectra were processed using UniDec (46), 
allowing molecular ions to be assigned and for the generation of the zero charge (deconvoluted) 
mass spectra. 
 
Cell Lysis, Immunoprecipitation and Immunoblotting 
 
HEK293 or U2OS cells were transiently transfected (TransIT LT1; Mirus) with vectors encoding 
various proteins according to figures and legends. For most experiments, after 40–48 hr and 
prior to harvesting, the cells were serum starved in DMEM for 1 hr at 37°C. The cells were then 
treated with vehicle or drug according to the following conditions.  For figure 2, cells were 
preincubated for 5 min at 37°C with DMSO or PDE inhibitors, followed by addition of 1 µM 
isoproterenol for a further 5 min at 37°C.  Cells were harvested in lysis buffer (25 mM HEPES, 
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 20 mM NaF, 2% glycerol, 0.3% Triton X-100) 
containing 100 nM okadaic acid and protease inhibitors. AKAP79 or AKAP18γ complexes were 
immunoprecipitated with anti-GFP rabbit IgG (Invitrogen) and protein A agarose for 2 hr at 4°C. 
Beads were washed 4 × 1 ml in lysis buffer. Proteins were separated on 4–12% NuPAGE 
gradient gels (ThermoFisher) and transferred to nitrocellulose membranes. Primary antibodies 
used include: PKA catalytic subunit mAb (BD Biosciences clone 5B), 1:1000; RIIα mAb (BD 
clone 40), 1:2000; GFP mAb (Santa Cruz Biotechnology sc-9996), 1:2000; phospho-PKA 
substrates rabbit mAb (Cell Signaling Technology (100G7E); 1:1000) were incubated with 
membranes overnight at 4°C in TBST/Blotto. The membranes were washed extensively in 
TBST, incubated with HRP-labeled secondary antibodies (Jackson Immunoresearch), washed 
as before and developed using ECL (ThermoFisher) on an Alpha Innotech MultiImage III with 
FluoroChem Q software. For re-probing, membranes were stripped with 1X Re-Blot Plus Strong 
(Millipore) for 15 minutes and then re-blocked in Blotto before incubation with primary antibodies 
again. 
 
Proximity Ligation Assays 
 
Cells were cultured on 12-18 mm poly-L-lysine coated glass coverslips.  After 24-30 hours, cells 
were starved for 1 hour and then stimulated with appropriate agonists (see figures).  Cells were 
fixed in PHEM (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl2, pH 6.9) containing 
4% paraformaldehyde (PFA) (Electron Microscopy Sciences) for 20 minutes.  Cells were 
washed extensively in PBS followed by permeabilization in PBS/0.5% Triton X-100 for 10 
minutes.  After several PBS washes, cells were processed for PLA according to (47) and 
manufacturer’s instructions using the Orange detection kit with anti-mouse and anti-rabbit 
reagents (OLink/Sigma-Aldrich).  Mouse anti-RIIα mAb (BD clone 40) and rabbit anti-PKAc 
(SCBT sc-903) were used to detect PKA holoenzymes.  Z-stacks of fluorescent images were 
collected using a Leica DMI6000B inverted microscope with a spinning disk confocal head 
(Yokagawa) and a CoolSnap HQ camera (Photometrics) controlled by MetaMorph 7.6.4 
(Molecular Devices).  Maximum intensity projections were quantified for puncta number using 
Fiji/ImageJ.  Images were smoothened and a duplicate image was created for use as a mask.  
The duplicate file was thresholded to capture as many puncta as possible without significant 
blending of densely packed signal.  The binary mask was then used to measure selected 
regions from the original image.  Total cell number per field of view was counted as DAPI-
stained nuclei. Intensity profiles of raw images were produced in MetaMorph. 
 
Live-cell FRET Imaging 
 
HEK293 or U2OS cells were cultured on 35-mm glass coverslip dishes (MatTek Corporation) or 
4-well glass bottom coverglass (ibidi). Cells were transiently transfected with cDNAs encoding 
different reporters alone, or together with either R2C2 fusion constructs or cDNAs encoding 
individual RII and C subunits. 24-48 hr after transfection, the cells were starved for 1 hour and 
then imaged in HEPES-Buffered Saline Solution (HBSS; 116 mM NaCl, 20 mM HEPES, 11 mM 
Glucose, 5 mM NaHCO3, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, pH 
7.4). All imaging was performed at ambient temperature (25 - 28oC). Cells were stimulated as 
indicated in individual figures. Fluorescence emission was acquired using a DMI6000B inverted 
microscope (Leica), an EL6000 component (fluorescent light source, filter wheel, ultrafast 
shutter; Leica) and a CoolSnap HQ camera (Photometrics), all controlled by MetaMorph 7.6.4 
(Molecular Devices). Dual-emission images were obtained simultaneously through a DualView 
image splitter (Photometrics) with S470/30 and S535/30 emission filters and 505 dcxr dichroic 
mirror (Chroma). Exposure times were 100-500 ms.  FRET changes within regions of interest 
were calculated as the ratio of measured fluorescent intensities from two channels (Mdonor, 
MindirectAcceptor) after subtraction of background signal. FRET ratio (YFP/CFP) changes were 
normalized to the average FRET ratio value before stimulation. 
 
CREB Phosphorylation and Immunofluorescence  
 
U2OSR2A/R2B/CA cells were plated onto poly-L-lysine coated coverslips and transfected with 
constructs encoding WT or M120A PKA-R2C2 fusion proteins as above.  After 36 hours, cells 
were starved for 1 hour in serum free DMEM-H (ThermoFisher).  Cells were then treated with 
indicated compounds for 30 minutes at 37oC.  Treated cells were rinsed in ice cold PBS and 
fixed in PBS containing 4% PFA. Cells were washed extensively in PBS, permeabilized for 10 
minutes in PBS containing 0.5% Triton X-100 and 0.2% BSA and then washed several times in 
PBS.  Cells were stained with anti-phospho-CREB serine 133 (Cell Signaling Technology 
(87G3); 1:500) overnight at 4oC.  Cells were washed in PBS and incubated with Alexa-488 
conjugated secondary antibodies (ThermoFisher; 1:400) for 1 hour at room temperature.  The 
cells were washed again in PBS twice and then incubated for 20 minutes with a 1:500 dilution of 
Texas Red-phalloidin (ThermoFisher) and DAPI.  After final washing in PBS and a distilled H2O 
rinse, coverslips were mounted in Prolong Diamond mounting media (ThermoFisher). Confocal 
microscopy was performed on a Zeiss LSM-510META laser scanning confocal microscope 
equipped with a Zeiss 63X, 1.4 numerical aperture, oil immersion objective.  Z-stacks were 
collected and processed for max intensity projections using the Zen 2009 control software. 
Laser power, scan area and pinhole were kept constant across all conditions.  Further image 
processing was performed in Fiji/ImageJ. Fluorescent intensity was quantified by measuring an 
ROI encompassing the nucleus and a non-stained region for background (after importing and 
splitting channels using the BioFormats package). Corrected total nuclear fluorescence was 
calculated according to the following formula: CTNF = Integrated Density – (Area of selected 
nucleus * Mean fluorescence of background selection). 
 
Bad Phosphorylation by Immunoblot 
 
U2OSR2A/R2B/CA cells were plated in 6-well dishes and co-transfected with constructs encoding 
WT or M120A PKA-R2C2 fusion proteins and pEBG-mBad (Cell Signaling Technology; 100-250 
ng/well).  After ~36 hours, cells were starved for 1 hour in serum free DMEM-H (ThermoFisher). 
Cells were preincubated for 5 min at 37°C with DMSO or 2 µM 1-NM-PP1, followed by addition 
of 1 µM iso for a further 5 min at 37°C. Cells were lysed in 25 mM HEPES, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 20 mM NaF, 2% glycerol, 1% Triton X-100, 0.5% 
deoxycholate plus 100 nM okadaic acid and protease inhibitors.  After cell debris removal by 
centrifugation, protein content of lysates was quantified using the BCA assay (ThermoFisher) in 
a 96-well plate.  Equivalent amounts of total lysate (12-15 µg/lane) was separated on Bolt 
gradient gels (ThermoFisher) and transferred to nitrocellulose. Membranes were incubated with 
primary antibodies overnight at 4°C in TBST/Blotto.  Prior to re-probing, membranes were 
stripped with 1X Re-Blot Plus Strong (Millipore) for 15 minutes and then re-blocked in Blotto.  
The following antibodies were used: phospho-Bad ser155 (Santa Cruz Biotechnology sc-
101641), 1:1000; PKA-C mAb (BD clone 5B), 1:1000; GST (Santa Santa Cruz Biotechnology 
sc-459), 1:1000; GST-HRP (GenScript), 1:1000); GAPDH (Santa Cruz Biotechnology sc-
25778), 1:1000. The membranes were washed extensively in TBST, incubated with HRP-
labeled secondary antibodies (Jackson Immunoresearch), washed as before and developed 
using ECL (ThermoFisher) on an Alpha Innotech MultiImage III with FluoroChem Q software.  
Quantification using densitometry of pSer155 Bad signal was performed using Fiji/ImageJ and 
normalized to corresponding GST immunoblot signal (for total Bad).   
 
Apoptosis Assay using Fluorescent DEVD Substrate 
 
U2OSR2A/R2B/CA cells were transfected with constructs encoding WT or M120A PKA-R2C2 fusion 
proteins.  Cells were re-plated onto poly-L-lysine coated 8-well chambered coverslips (ibidi) and 
incubated overnight in vehicle or 50µM etoposide (SCBT).  Isoproterenol (1 µM) and the long-
acting b-agonist formoterol (1 µM) (an attempt to keep b-AR-PKA signaling high during the time 
course of the overnight treatment) were also added to appropriate wells.  After 16 hours, 
CellEvent™ Caspase-3/7 Green Detection Reagent (ThermoFisher) was added to cells at a 
final concentration of 2 µM for 1 hour at 37oC.  Cells were fixed by direct addition of PFA (16%, 
Electron Microscopy Sciences) to 4% for 5 minutes.  Media was then replaced with PBS 
containing 4% PFA for another 10 minutes.  Cells were washed extensively in PBS, 
permeabilized for 10 minutes in PBS containing 0.5% Triton X-100 and 0.2% BSA and then 
washed several times in PBS.  Cells were incubated with DAPI for 20 minutes and stored in 
PBS.  For imaging, PBS was replaced with Vectashield (Vector Labs).  Images were acquired 
on our Leica spinning-disk confocal microscope as described above. 
 
Cell Growth Assay 
 
U2OSR2A/R2B/CA/CB (R2C2-M120A stable, Cb KO) cells were created as described above, using a 
sgRNA targeting PRKACB (sequence: 5’-CATGGCATAATACTGTTCAG-3’).  Several clones 
with interruptions of the PRKACB gene were expanded and subjected to cell growth assays 
using the CellTiter 96® AQueous One Solution cell proliferation assay (Promega, Madison, WI).  
Cells were plated in a 96-well plate in triplicate at 1000 cells per well in 100 µl.  After 24 hours, 
20 µl assay solution was added to each well and cells were grown another 3 hours at 37oC, 5% 
CO2.  Absorbance at 490 nm was read on a POLARstar Omega plate reader (BMG Labtech).  
Counts were background subtracted using wells containing only growth media.   
 
Fig. S1. 
Additional data related to figure 1.  (A) Raw EM micrograph of AKAP79-PKA holoenzyme 
complexes.  Purified proteins were assembled into complexes and processed by the GraFix 
method (43).  Dilute samples were applied to carbon coated grids and negative-stained with 
uranyl formate.  Grids were imaged on a Tecnai T12 TEM at 0.7-1.5 micron defocus ranges.  
Representative particles picked for further analysis are boxed (yellow squares). (B) Native nESI 
mass spectrum of RII+C+AKAP297-427 complexes. Indicated are the charge states of each of the 
observed and annotated molecular ions (see associated tables S1 and S2). Data were acquired 
on the Synapt G2-Si (Waters). (C) Native nESI mass spectrum of RII+C complexes without 
additional cAMP. The 25+ charge state of the 2RII:C:ncAMP complexes are presented (see 
associated table S3).  Data were acquired on the Exactive™ Plus EMR Orbitrap 
(ThermoScientific). (D) Native nESI mass spectrum of RII+C complexes with additional cAMP (5 
μM; RII:C:cAMP ratio of 1:1:2). The 25+ charge state of the 2RII:C:ncAMP complexes are 
presented (see associated table S3). Data were acquired on the Exactive™ Plus EMR Orbitrap 
(ThermoScientific). 
 
 
 
  
 
Fig. S2 
Additional data related to figure 2.  Anchored PKA holoenzymes remain associated during 
submaximal cAMP pulses and can re-form quickly upon removal of supraphysiological stimuli. 
(A) HEK293 cells expressing AKAP18g-GFP and RIIa-V5 were stimulated for 5 minutes with 1 
µM isoproterenol alone or after 5-minute pre-incubation with PDE inhibitors as indicated.  
AKAP18g was immunoprecipitated, and immune complexes and lysates were probed for 
associated PKA subunits by Western blotting.  Detection of phosphorylated PKA substrates was 
used to confirm activation of PKA signaling.  (B) HEK293 cells expressing AKAP79-GFP and 
RIIa-V5 were stimulated for 5 minutes with indicated compounds alone or after 5-minute pre-
incubation with PDE inhibitors as above.  Forskolin/IBMX treatment was for 20 minutes. 
AKAP79 was immunoprecipitated and immune complexes and lysates were probed for 
associated PKA subunits by Western blotting.  Detection of phosphorylated PKA substrates was 
used to confirm activation of PKA signaling. (C) FRET recordings in HEK293 cells expressing 
the paired RII-CFP/PKAc-YFP biosensor upon PGE1 stimulation in the presence (red) or 
absence (black) of rolipram. (D) Representative images from PGE1 treated cells.  (E) 
Representative images from PGE1 + rolipram treated cells.  (F) FRET recordings in HEK293 
cells expressing the ICUE3 cAMP biosensor upon PGE1 stimulation in the presence (red) or 
absence (black) of rolipram. (G) HEK293 cells expressing AKAP79-GFP and RIIa-V5 were 
stimulated for 5 minutes with 1 µM isoproterenol or were stimulated with iso + rolipram followed 
by a washout period of different lengths in which drug was removed and replaced with fresh 
serum-free DMEM. AKAP79 was then immunoprecipitated, and immune complexes and lysates 
were probed for associated PKA subunits.  Detection of phosphorylated PKA substrates was 
used to confirm activation of PKA signaling. (H) HEK293 cells on glass coverslips were 
stimulated as described above and then fixed in 4% PFA for proximity ligation assays. Cells 
were processed for detection of the interaction between RII and C with the Orange PLA 
detection kit (Sigma-Aldrich) and co-stained for DAPI to detect nuclei. (I) HEK293 cells 
expressing AKAP18g-GFP were stimulated for 5 minutes with 1 µM isoproterenol alone or after 
5-minute pre-incubation with rolipram (10 µM).  AKAP18g was immunoprecipitated, and immune 
complexes and lysates were probed for associated PKA subunits by Western blotting. 
 
  
 Fig. S3 
Additional data related to figure 3. (A) Immunoblotting using phospho-PKA substrates 
antibodies of cell lysates from wild-type U2OS and U2OSR2A/R2B/CA cells after treatment with 
isoproterenol (1 µM, 5 min).  (B)  Immunoblotting of wild-type U2OS, U2OSR2A/R2B/CA, 
U2OSR2A/R2B/CA-R2C2 stable, and two clonal lines of U2OSR2A/R2B/CA/CB-R2C2 stable (Cb KO) cells 
with antibodies against PKA C-subunit.  These blots were assembled from two different 
experiments to demonstrate stable expression of the R2C2 fusion protein. (C) MTS assay on 
triple knockout cells stably expressing R2C2-M120A and two clones of quadruple knockout lines 
derived from these cells. (D) AKAR4NES cytoplasmic FRET recordings in Iso-stimulated 
U2OSR2A/R2B/CA cells expressing “kinase-dead” R2C2 K72A. (E) AKAR4NLS nuclear FRET 
recordings in wild-type U2OS cells in response to forskolin/IBMX treatment. (F) AKAR4NLS 
nuclear FRET recordings in U2OSR2A/R2B/CA cells expressing FKBP-RII and FRB-C in response 
to stimulation with isoproterenol and rolipram (1 µM/10 µM), in the absence (orange) or 
presence (blue) of rapamycin (100 nM).   
  
Fig. S4 
Additional data related to figure 4.  (A) Wild-type U2OS and U2OSR2A/R2B/CA were transfected 
with a plasmid encoding GST-BAD.  Cells were treated with isoproterenol (1 µM) or vehicle for 5 
minutes.  Immunoblot detecting BAD pSer155 and total BAD (GST).  (B) U2OSR2A/R2B/CA 
transiently expressing mitochondrially-targeted GFP, D-AKAP-1 and GST-BAD were fixed, 
stained and imaged using confocal microscopy.  (C) U2OSR2A/R2B/CA transiently expressing 
mitochondrially-targeted GFP, D-AKAP-1 and GST-BAD were fixed, processed for proximity 
ligation and imaged using confocal microscopy.  Fluorescence is shown in grayscale except for 
composite images. 
 
  
Table S1:  Theoretical and observed m/z values for each of the observed complexes of RII, C, 
AKAP79297-427 with or without cAMP as measured by native MS. Data were acquired on the 
Synapt G2-Si (Waters). 
Complex Charge 
state 
am/z 
theoretical 
m/z 
observed 
bdelta 
C 12 3834.9 3834.4 -0.5 
 13 3540.0 3535.1 -4.9 
RII 12 4006.3 4004.7 -1.6 
 13 3698.2 3699.4 1.2 
 14 3434.1 3433.4 -0.7 
RII:cAMP 12 4033.8 4034.0 0.2 
 13 3723.6 3723.9 0.3 
RII:2cAMP 12 4061.2 4061.4 0.2 
 13 3748.9 3747.9 -1.0 
2RII:4cAMP 18 5414.6 5419.3 4.7 
 19 5129.7 5130.7 1.0 
RII:C 17 5534.6 5540.6 6.0 
 18 5227.2 5228.5 1.3 
 19 4952.1 4951.7 -0.4 
 20 4704.6 4704.2 -0.4 
2RII:C:2cAMP 22 6491.6 6497.4 5.8 
 23 6209.4 6213.7 4.3 
 24 5950.7 5952.5 1.8 
 25 5712.7 5717.7 5.0 
2RII:2C 24 7840.3 7834.7 -5.6 
 25 7526.7 7538.3 11.6 
 26 7237.2 7260.4 23.2 
 27 6969.2 6977.7 8.5 
2RII:C:AKAP:2cAMP 23 6868.4 6872.0 3.6 
 24 6582.2 6582.5 0.3 
 25 6319.0 6320.3 1.3 
 26 6076.0 6077.7 1.7 
2RII:2C:AKAP (P) 26 7820.2 7834.7 14.5 
 27 7530.6 7538.3 7.7 
 28 7261.6 7260.4 -1.2 
 29 7011.3 7006.1 -5.2 
 30 6777.6 6782.0 4.4 
a Theoretical masses (and m/z values) of the complexes were calculated using the native experimental mass data for 
the individual subunits under the same experimental conditions.  
 
b Difference between theoretical and observed values arise due to incomplete desolvation and adducts of Na+ that 
are typical of these types of native mass spectrometry analyses.  
Table S2:  Theoretical and experimentally computed masses (Da) of each of the observed 
complexes of RII, C, AKAP79297-427 with or without cAMP following native MS (Supplementary 
Table 1; Fig 1). Data were acquired on the Synapt G2-Si (Waters). 
Complex aTheoretical 
mass (Da) 
Experimental  
mass (Da) 
bDelta 
mass (Da) 
R:C 94,071 94,000 71 
2R:C:2cAMP 142,793 142,600 193 
2R:C:AKAP:2cAMP 157,949 157,800 149 
2R:2C 188,142 188,100 42 
2R:2C:AKAP 203,298 203,200 98 
a Theoretical masses of the complexes were calculated using the native experimental mass data for the individual 
subunits under the same experimental conditions.  
 
b It should be noted that the difference between theoretical and observed values arise largely due to incomplete 
desolvation and adducts of Na+ that are typical of these types of native mass spectrometry analyses. Consideration 
should also be given to the multiple phosphorylated forms of the catalytic subunit C, given that an average of 7 (5 – 
10) phosphate molecules are typically observed for heterologously expressed catalytic enzyme (Ref. 10). 
 
  
Supplementary Table 3:  Theoretical and observed m/z values for the 25+ charge state of the 
2RII:C:ncAMP complexes, without or with additional cAMP (5 μM; RII:C:cAMP ratio of 1:1:2), as 
measured by native MS. Data were acquired on the Exactive™ Plus EMR Orbitrap 
(ThermoScientific). 
RII:C:cAMP 
Ratio 
  Complex Charge 
state 
am/z 
theoretical 
m/z 
observed 
bdelta 
1:1:0 2RII:C:2cAMP 25 5706.1 5706.6 0.5 
 2RII:C:3cAMP 25 5719.3 5715.8 -3.5 
 2RII:C:4cAMP 25 5732.4 5728.4 -4.0 
1:1:2 2RII:C:2cAMP 25 5706.1 5712.8 6.7 
 2RII:C:4cAMP 25 5732.4 5732.8 0.4 
a Theoretical masses (and m/z values) of the complexes were calculated using the native experimental mass data for 
the individual subunits under the same experimental conditions.  
 
b Difference between theoretical and observed values arise due to incomplete desolvation and adducts of Na+ that 
are typical of these types of native mass spectrometry analyses. 
 
 
